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9791-Year Results From the
NOTION Randomized
Clinical Trial
No News Is Good News?The NOTION (Nordic Aortic Valve Intervention) trial
compared transcatheter aortic valve replacement
(TAVR) versus surgical aortic valve replacement
(SAVR) in predominantly low-risk patients (1). Avail-
able evidence is consistent in suggesting that TAVR is
associated with a better immediate outcome, given
the less invasive nature of the procedure. However,
the less favorable immediate outcome reported
with SAVR is offset by improved survival, which is
the primary therapeutic goal for patients at low- and
intermediate-risk.
As partly recognized by Thyregod et al. (1), there
are several study limitations to acknowledge:
 Patients with signiﬁcant concomitant coronary
disease were not recruited, so that nearly 90% of
patients were excluded at enrollment. In other
words, it is not for “all-comers,” as the title says.
 Hospital costs are higher for TAVR than SAVR pro-
cedures, and the hypothesis tested in the study would
result in an unsustainable healthcare expenditure.
 The “modern TAVR” is compared with the “ancient
SAVR.” However, it should be taken into consider-
ation that, at present, SAVR can be performed using
different approaches (e.g., minimally invasive sur-
gery, sutureless bioprostheses) that may compete
well with current interventional techniques.
 The rate of post-operative cardiogenic shock and
major/life-threatening bleeding in this low-risk
SAVR population seem unusually high (10.6% and
>20%).
 The high rate of post-operative pacemaker im-
plantation in the TAVR group (34.1%) seems to be
correlated with the prosthetic device used rather
than with TAVR per se. This complication deserves
further discussion, given the well-known associa-
tion between pacemaker stimulation and ventric-
ular deterioration.
 At 1-year follow-up, TAVR patients had more dys-
pnea compared with SAVR patients, likely due
to paraprosthetic regurgitation. This has been
frequently described as a complication occurring
with current-generation TAVR devices and has been
associated with increased mortality. However, the
mortality rate after TAVR in the NOTION trial is 1 of
the lowest ever reported, and the short follow-up
period can account for this positive ﬁnding.*Giuseppe Santarpino, MD
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Than More Dyspnea
More or Less?With interest we read the paper by Thyregod et al. (1)
on transcatheter aortic valve replacement (TAVR)
versus surgical aortic valve replacement (SAVR) in
patients with severe aortic valve stenosis. TAVR has
been considered an acceptable treatment option for
patients with inoperable severe aortic valve stenosis
or at high risk for surgery (2). The NOTION (Nordic
Aortic Valve Intervention Trial) study was the ﬁrst
randomized trial comparing TAVR with SAVR in an
all-comers patient population with severe symptom-
atic aortic valve stenosis regardless of their predicted
morality score. It was a multicenter, randomized,
nonblinded, superiority trial.
No signiﬁcant differences were found regarding
death from any cause, stroke, or myocardial infarc-
tion; cardiovascular mortality; or prosthesis re-
intervention after 1 year. Power calculations in the
trial were far too weak to detect a small (z3%)
absolute difference in primary outcome between
groups. Need for permanent pacemaker implantation
(38.0% vs. 2.4%; p < 0.001), New York Heart Associ-
ation functional class II at 1 year (29.5% vs. 15.0%;
p ¼ 0.01), and moderate-to-severe regurgitation at
1 year (15.7% vs. 0.9%; p < 0.001) were all better in
the SAVR group. Bleeding, acute kidney injury,
cardiogenic shock, new-onset atrial ﬁbrillation, and
duration of indexed hospitalization were better in the
TAVR group, although they did not corroborate to a
worse overall 1-year outcome or a difference in the
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980number of hospitalizations or days hospitalized
within the ﬁrst year.
Considering that symptomatic relief is the primary
indication for aortic valve replacement (2), we are
surprised that the authors did not conclude correctly
using the evidence from their own results. A conclu-
sion that one procedure could not be recommended
over the other seems misleading when SAVR patients
were less symptomatic 1 year after the procedure. If
less dyspnea is not enough to recommend SAVR to
such patients, what is? Signiﬁcant residual aortic
regurgitation is a known factor responsible for worse
outcome in patients after TAVR (3).
Although the nature of the trial as a superiority
trial is clearly stated in the Methods section, the
conclusions appear to disregard that statement.
Concluding simply that TAVR is not superior to SAVR
in the lower-risk symptomatic aortic valve stenosis
population is far more appropriate than the one
stating an inability to recommend or refute one pro-
cedure over the other. The authors should be
congratulated on their contribution.*Tomislav Kopjar, MD, PhD
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Weighing Complications Against Functional OutcomesTo our knowledge, no randomized trials comparing
transcatheter aortic valve replacement (TAVR) versus
surgical aortic valve replacement (SAVR) in an
all-comers population including intermediate- andlow-risk patients had been conducted before the
NOTION (Nordic Aortic Valve Intervention) trial.
Therefore, improved survival after SAVR compared
with TAVR has not been proven as suggested by
Dr. Santarpino and colleagues.
Our trial aimed to compare TAVR versus SAVR
and therefore excluded patients with signiﬁcant cor-
onary artery disease. We screened all patients 70 years
of age or older referred to intervention and offered
all eligible patients trial inclusion. About one-third
of patients were not offered surgery, some were not
technical suitable for TAVR, and others were not
willing to participate. However, the majority of
eligible patients were enrolled. The purpose of our
trial was not to examine health economics. The cost of
TAVR is currently higher than surgery but will most
likely change over time. Also, the length of hospital
stay was at an average 4 days shorter for TAVR pa-
tients but more received a pacemaker. We agree that
newer surgical prostheses and minimally invasive
aortic valve surgery should also be compared with
TAVR in future trials. Our trial was conducted at 3
large cardiac surgical centers and the Valve Academic
Research Consortium 2 deﬁnitions were used for
event adjudication (1). We believe the outcomes
represent daily practice well. The pacemaker im-
plantation rate was higher in the TAVR group and well
known to be related to the speciﬁc TAVR system used
(2), but no studies have demonstrated an association
between pacemaker implantation and mortality (3).
The rate of moderate-to-severe paravalvular leak-
age (PVL) was about 15% for TAVR in our trial, and
PVL has previously been associated with increased
mortality (4). The issue of PVL should be resolved
before the routine use of TAVR in lower-risk patients.
In current clinical practice, the introduction of
3-dimensional aortic annular measurements using
cardiac computed tomography scans and newer TAVR
systems designed to minimize PVL have decreased
the rate of moderate-to-severe PVL to 3% to 4%
(S.Kodali et al., 2015 ACC meeting, San Diego, CA).
Intervention for severe aortic valve stenosis is
indicated for both symptomatic as well as asymp-
tomatic patients with compromised cardiac function,
rapid disease progression, or positive exercise test (5).
The primary outcome of the NOTION trial was the
composite rate of death from any cause, stroke,
or myocardial infarction 1 year after intervention.
With superiority testing, we could not demonstrate a
signiﬁcant difference between TAVR versus SAVR.
As mentioned by Dr. Kopjar and colleagues, other
procedural complications were signiﬁcantly different
between groups. More surgical patients had no dys-
pnea compared with transcatheter patients 1 year
